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tag for the assessment of alum adjuvant
particle biodisposition
Housam Eidi1,3*, Marie-Odile David1, Guillemette Crépeaux3, Laetitia Henry1, Vandana Joshi1, Marie-Hélène Berger2,
Mohamed Sennour2, Josette Cadusseau3,4, Romain K. Gherardi3† and Patrick A. Curmi1†Abstract
Background: Aluminum oxyhydroxide (alum) is a crystalline compound widely used as an immunologic adjuvant
of vaccines. Concerns linked to alum particles have emerged following recognition of their causative role in the
so-called macrophagic myofasciitis (MMF) lesion in patients with myalgic encephalomyelitis, revealing an unexpectedly
long-lasting biopersistence of alum within immune cells and a fundamental misconception of its biodisposition.
Evidence that aluminum-coated particles phagocytozed in the injected muscle and its draining lymph nodes can
disseminate within phagocytes throughout the body and slowly accumulate in the brain further suggested that
alum safety should be evaluated in the long term. However, lack of specific staining makes difficult the assessment of
low quantities of bona fide alum adjuvant particles in tissues.
Methods: We explored the feasibility of using fluorescent functionalized nanodiamonds (mfNDs) as a permanent label
of alum (Alhydrogel®). mfNDs have a specific and perfectly photostable fluorescence based on the presence
within the diamond lattice of nitrogen-vacancy centers (NV centers). As the NV center does not bleach, it allows
the microspectrometric detection of mfNDs at very low levels and in the long-term. We thus developed fluorescent
nanodiamonds functionalized by hyperbranched polyglycerol (mfNDs) allowing good coupling and stability of
alum:mfNDs (AluDia) complexes. Specificities of AluDia complexes were comparable to the whole reference vaccine
(anti-hepatitis B vaccine) in terms of particle size and zeta potential.
Results: In vivo, AluDia injection was followed by prompt phagocytosis and AluDia particles remained easily detectable
by the specific signal of the fND particles in the injected muscle, draining lymph nodes, spleen, liver and brain. In vitro,
mfNDs had low toxicity on THP-1 cells and AluDia showed cell toxicity similar to alum alone. Expectedly, AluDia elicited
autophagy, and allowed highly specific detection of small amounts of alum in autophagosomes.
Conclusions: The fluorescent nanodiamond technology is able to overcome the limitations of previously used organic
fluorophores, thus appearing as a choice methodology for studying distribution, persistence and long-term neurotoxicity
of alum adjuvants and beyond of other types of nanoparticles.
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The understanding of how the body handles small parti-
cles in the long-term, especially those which interact
with the immune system, is a major objective of recent
research [1]. For example, concerns linked to the use of
aluminum particles as vaccine adjuvants [aluminum oxy-
hydroxide (“alum”)] have emerged following recognition
of their role at the origin of the focal lesion called mac-
rophagic myofasciitis (MMF). This revealed a fundamen-
tal misconception of the fate of alum in the organism
pointing out its unexpectedly long-lasting biopersistence
within immune cells [2]. It also demonstrated their cap-
acity to migrate to the lymphoid organs, to disseminate
throughout the body within monocyte-lineage cells, and
to slowly accumulate in the brain [3]. Millions of
humans have received vaccines adjuvanted with alum.
Overall safety of these vaccines has been regarded as ex-
cellent at the level of the population [4], but adverse ef-
fects have also been reported [5, 6]. It seems very likely
that a small proportion of presumably susceptible indi-
viduals exposed to particulate materials with adjuvant
effects, e.g. alum adjuvants or breast implant-derived sili-
cone, may develop progressive systemic and neurologic
autoimmune/inflammatory manifestations or “ASIA” [7].
These individuals typically show long-term persistence
of particles within the monocyte-lineage cells at either
the site of previous immunization with alum-containing
vaccines, i.e. MMF, or in the vicinity of leaky breast im-
plants [8].
Alum particles have neither fluorescent nor magnetic
properties. Their detection in tissues therefore represents a
difficult challenge. Khan et al. [3] analyzed biodisposition
of alum particles in mice by tracking fluorescent alum sur-
rogates, such as alum-like hybrids which were composed
of a rhodamine core coated with precipitated aluminum
hydroxide. This approach has limitations since the precipi-
tated aluminum hydroxide used by Khan et al. [3] is similar
but not strictly identical to the aluminum oxyhydroxide
used in vaccines [9]. Indeed, particles may exhibit strikingly
different properties according to their physicochemical
properties, the main parameters being their size, shape,
zeta potential and chemical composition [10].
The present study aimed at evaluating the possibility
of constructing a fluorescent complex highly relevant to
vaccine by tagging the alum adjuvant itself (Alhydrogel®)
using modified fluorescent nanodiamonds (mfNDs).
MfNDs have unique fluorescence properties, which allow
their detection at very low levels and over a very long-
term period [11–13]. Indeed, their fluorescence, based
on the presence of nitrogen-vacancy centers (NV centers)
within the nanodiamond crystal lattice, is perfectly
photostable with neither bleaching nor blinking. mfNDs
were reported as biocompatible fluorescent particles
with very low toxicity [14]. These properties overcomethe limitations of organic fluorophores or quantum dots,
i.e. photobleaching and toxicity [15–17]. In our last paper
we showed that fNDs functionalized with hyperbranched
polyglycerol (mfNDs) could be promising tools for bio-
medical research [18].
In the present study, Alhydrogel® used in vaccines was
tagged with mfNDs forming the AluDia complex. We
first determined, under different conditions, AluDia
physicochemical properties, including morphology, size,
zeta potential and stability. Then, we examined the fate
of AluDia after injection into mouse muscle in terms of
granuloma formation and persistence, and biodistribu-
tion to distant organs. Finally, we analyzed the effects of
AluDia administration to macrophages and neurons in
culture, including cytotoxicity, internalization, stability
and intracellular behavior.
Methods
Preparation and characterization of the AluDia complex
Reagent grade chemicals were purchased from Sigma–
Aldrich (France) and used as received. The suspension
of aluminum oxyhydroxyde or alum (Alhydrogel®) 2 wt
% in water was purchased from Invivogen. Commercially
available anti-hepatitis B vaccine (ENGERIX B®, GlaxoS-
mithKline Inc., Evreux, France) was used as a reference
for its physico-chemical specificities.
Fluorescent nanodiamonds preparation
Fluorescent nanodiamonds (fNDs) were prepared from a
synthetic micron diamond powder (Element Six PDA999
80–100 mesh) as already described [13]. The creation of
NV centers in the crystal, the origin of fluorescence, was
done by electronic irradiation followed by annealing at
850 °C under vacuum. To convert the micron size to nano
size powder, nitrogen jet milling followed by planetary ball
milling was used. Then fNDs were extracted, decontami-
nated by treatment with harsh acids (HF/HNO3) and
washed with water. An additional treatment with perchlo-
ric acid was used to improve cleaning and saturate the
surface with oxygenated chemical groups [18].
Synthesis of modified fluorescent nanodiamonds
A total of 5 mg fNDs powder was dispersed in 3 mL
hyperbranched polyglycerol (HPG) and the reaction car-
ried out at 140 °C for two hours as described by Boudou
et al. [18]. The mfND sample was isolated from the re-
action medium by dissolution of the free polymer and
residual glycidol in methanol and subsequent centrifuga-
tion at 15,000 x g for 30 minutes. This procedure was
repeated three times. The final pellet was further washed
by three repeated dispersions in water followed by cen-
trifugation at 15,000 x g for 30 minutes. The final mfND
pellet was dispersed in water for further use.
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Before use, the suspensions of mfNDs (1.3 g/L) and
alum (10 g/L) in water were sonicated for five minutes.
The complex (AluDia) was obtained by mixing the Alhy-
drogel® and mfND suspensions at a ratio of 1:17 v/v
followed by a thorough agitation and a few minutes of
sonication. The AluDia suspension was then diluted to
reach the appropriate concentration in PBS.Size and zeta potential measurements
We characterized the size distribution and zeta potential
of mfNDs, alum and AluDia as well as of the particles
present in a commercially available anti-hepatitis B vac-
cine (HBV, ENGERIX B® GlaxoSmithKline Inc., Evreux,
France) using dynamic light scattering. Nanoparticles/
agglomerates were suspended in water, to a concentra-
tion <1 mg/mL. pH/ conductivity was controlled by an
autotitrator Delsa™Nano AT, and the suspension was an-
alyzed using a Delsa Nano C Particle Size apparatus,
(Beckman Coulter, Villepinte, France) equipped with two
658 nm laser diode sources (power 30 mW) and a
temperature controller (from 15 to 90 °C). Size distribu-
tion was approximated by photon correlation spectros-
copy (PCS, also called dynamic light scattering) at a
scattering angle of 165°. Scattering data were collected
for 70 individual measurements at a constant scattering
angle and averaged for each sample. When possible, the
particle zeta potential was determined by measuring the
electrophoretic movement of the charged particles under
an applied electric field. Scattered light was detected at a
15° angle and a temperature of 25 °C.In vitro and in vivo experiments
Cell culture
We used THP1 and NSC-34 as in vitro models. These
cell lines were used to assess particle internalization,
intracellular colocalization of alum and mfNDs particles
and their cytotoxicity.
The human THP-1 monocyte cell line was grown in
RPMI-1640 medium supplemented with 10 % fetal bovine
serum, 2 mM L-glutamine, 100 U/mL penicillin, and 100
mg/mL streptomycin, under standard conditions (humidi-
fied chamber at 37 °C and 5 % CO2 atmosphere).
The murine NSC-34 cells, a hybrid cell line consisting
of motor neurons fused with neuroblastomas, were grown
in D-MEM culture medium (Fisher Scientific, Illkirch,
France), complemented with 10 % heat-inactivated fetal
bovine serum (Gibco BRL, Illkirch, France), 50 U/mL
penicillin, and 50 mg/mL streptomycin. Cells were incu-
bated in a humidified chamber at 37 °C and 5 % CO2 at-
mosphere. THP-1 and NSC-34 were grown in suspension
and in two-dimensional flasks, respectively.Evaluation of cell viability by MTT assay
To assess cell viability, cells were seeded in 96-well plates
at a density of 1.3 x 103 cells/well in 100 μL of medium.
Particle toxicity in cells was assessed using the 3-(4, 5-
dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide, or
MTT, cell viability assay. Cells were treated with different
doses of alum, mfNDs and AluDia particles two days after
the beginning of the culture. The viabilities of cultured
cells were assessed 72 hours after treatment with mfNDs,
alum and AluDia particles following the manufacturer’s
protocol. Briefly, cells were incubated at 37 °C with 10 μL/
well of MTT solution for 70 minutes. After a 3-hour incu-
bation at 37 °C under 5 %CO2, the MTT solution was dis-
carded carefully and the blue formazan crystals, formed by
reduction of MTT, were dissolved in dimethyl sulfoxide
(DMSO [67-68-5], Sigma–Aldrich). The amount of forma-
zan was determined spectrophotometrically by measuring
the absorbance at λ = 540 nm using a microplate reader
(Model 3550-UV, Bio-Rad, Marnes-la-Coquette, France).
Each concentration was tested in quadruplicate and three
independent experiments were performed. Since absorb-
ance is proportional to the number of living cells, cell via-
bility was represented by the absorbance ratio of exposed
to control cells.
Since incubation with aluminum adjuvant was previ-
ously shown to increase the mitochondrial activity [19]
which might interfere with MTT results, cell toxicity
was confirmed by the Trypan blue test (data not shown).
Mice model
All animal experiments were conducted in accordance
with the European guidelines for animal care. Eight male
8- to 10-week‐old C57BL/6 mice with an average weight
of 25 g were used. Sixteen female 7-week-old CD1 mice
were used to observe the granuloma size in injected
muscles with AluDia particles at 45, 135, 180 and 270
days post injection (four mice per time). Mice were pro-
tected from Al‐containing materials, fed with manufac-
tured animal food and water ad libitum, and exposed to
12:12 light/dark cycles.
AluDia administration
The dose of AluDia administered to mice was calibrated
to mimic the mean number of human adult doses of the
ENGERIX B® vaccine received by MMF patients. A dose
of 20 μL AluDia, corresponding to 400 μg Al/kg, was
injected in the tibialis muscle of mice.
Tissue preparation and particle counting
On days 7 and 21 post-injection mice were transcardially
perfused with PBS under terminal anesthesia. Tissues and
organs were removed and quickly frozen. Whole brains
were serially cut into 40 μm coronal cryosections, spleen
and muscle into 20 μm, and draining lymph nodes (DLNs)
Table 1 Diameter distribution and zeta potential values of
mfND, Alhydrogel®, AluDia and ENGERIX® alum particles
Particle types Diameter (nm) Zeta potential (mV)
mfNDs 80 ± 30 - 29 ± 3
Alhydrogel® 3240 ± 200 +25 ± 4
AluDia 2930 ± 230 +28 ± 2
ENGERIX® alum 3820 ± 570 +30 ± 5
Size and zeta potential data were obtained in PBS at pH7.2 and 25 °C. Three
different samples of each particle preparation were used in size and zeta
potential analyses (n = 3 per particle type). Size and zeta potential were
measured in triplicate in each sample (triplicate analyses)
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or treatment. Tissue sections were successively deposited
on 10 different Superfrost®-plus slides in order to obtain
10 identical series, thus allowing determination of total
particle content by multiplying by 10 the number of parti-
cles found in a single series.
Immunohistochemistry and Morin staining
CD11b labeling was used to observe the monocyte-
lineage cells, including macrophages in injected muscles.
Tissue sections were fixed by 2 % paraformaldehyde
(PFA) and rinsed three times with PBS before using the
immunodetection Kit (M.O.M™ kit, Vector®, Peterbor-
ough, UK). Anti-CD11b (MAC-1) (AbD SEROTEC -
product code: MCA74GA, Oxford, UK) was used as “rat
anti-mouse” primary antibody (1/200). Rat IgG produced
in the donkey and coupled to Alexa Fluor 488® fluoro-
chrome (Jackson ImmunoResearch, Suffolk, UK) was
used as the secondary antibody. After rinsing with PBS,
the slides were coverslipped using Vectashield® aqueous
medium (Eurobio, Courtabœuf, France). Aluminum was
stained after tissue section with Morin (M4008‐2G,
Sigma‐Aldrich) that was dissolved in a solution consist-
ing of 0.5 % acetic acid in 85 % ethanol [20]. Formation
of a fluorescent Morin complex with aluminum was de-
tected by the presence of an intense green fluorescence
with a characteristic 520 nm emission under a 420 nm
excitation.
Epifluorescence microscopy and microspectrometry
Fluorescence observations were made using a Zeiss Axio-
plan 2 microscope, equipped with a 1.4 NA oil immersion
objective. Fluorescence images were obtained with a Prince-
ton Instruments EMCCD Camera Rolera em–c2, with typ-
ical exposure times. For mfNDs detection, a DPSSL 532
nm (200 mW) laser beam was used as the illuminating
source and was guided to the microscope by an optical
fiber. A long pass 600 nm emission filter was used to collect
only wavelengths higher than 600 nm. Spectra of the fluor-
escent spots were acquired by focusing the fluorescent ob-
ject emission from the microscope onto an Acton SP2150i
spectrometer (Princeton Instruments, Buckinghamshire,
UK), and detected with a PIXIS–100B– eXcelon CCD cam-
era (Princeton Instruments).
Electron microscopy
Cells were seeded for 24 hours in standard conditions
(conditions similar to those used for fluorescence experi-
ments). AluDia particles were added to the cell culture
medium and incubated for 24 hours at 37 °C. Cells were
then fixed in 4 % glutaraldehyde phosphate buffer for 45
minutes at room temperature. After dehydration with a
graded series of ethanol, the cells were embedded in
Epon resin. Ultrathin sections of the resin block werethen cut (100 nm thickness) and stained with 2 % uranyl
acetate for a higher contrast imaging. Electron microscopy
observations were done with a high-resolution transmis-
sion electron microscope (HR-TEM-STEM, Tecnai F20ST
operating at 200 keV with a field emission gun).
Energy-dispersive X-ray (EDX) analysis coupled with
STEM was used to identify the elemental composition of
AluDia complex. High resolution images were recorded
at approximately Scherzer defocus on a CCD multiscan
camera after astigmatism corrections, and eventually fil-
tered via the Digital Micrograph software.Statistical analyses
One-way ANOVA with Fisher’s Least Significant Differ-
ence (LSD) post hoc comparisons at 95 % confidence
interval was used for statistical comparisons in the MTT
assay. All statistical analyses were performed with the
SigmaStat 3.11 software package (Sistat Inc., USA).Results and discussion
Particle characterization
As assessed by dynamic light scattering of particles in
PBS at pH7.2, mfNDs appeared to be of nanometric size
(about 80 nm) whereas agglomerates of alum alone, Alu-
Dia and Engerix® alum formed particles of micrometric
diameter with peaks from 2,900 nm to 3,800 nm (Table 1
and Fig. 1). Our characterization data showed that the
zeta potential of mfNDs is slightly negative (−29 mV)
whereas those of alum, AluDia, and ENGERIX® particles
are slightly positive, ranging from +25 to +30 mV
(Table 1). Thus, in the physiological conditions we used,
AluDia particle size and zeta potential were very similar
to those of alum alone or alum adsorbed with HBV anti-
gen. In addition, the size and charge of the AluDia parti-
cles remained stable during 15 days in PBS as well as in
DMEM culture medium supplemented with 5 % (v/v)
fetal bovine serum at 4 °C (data non shown). Thus, the
physico-chemical properties of the AluDia complex were
as close as possible to those of the HBV vaccine, making
mfNDs relevant for further investigation as a tag for
alum particle tracking.
Fig. 1 Particle characterization by microscopy. a: TEM analysis of fND aggregates that contained very small mfNDs (few nm). b: The red specific
fluorescence of mfNDs excited by a 532 nm laser source. c: mfNDs luminescence spectrum with a specific peak at 700 nm. d: Schematic
representation of the possible hydrogen bonds between the hydroxyl groups of the HPG chains and that of alum. e and f: The nanofibrous
morphology of alum and vaccine aggregates (ENGERIX B®) by TEM analysis. g and h: The AluDia complex analyzed by TEM in which alum
keeps its nanofibrous morphology and is loaded by non-fibrous, electron dense mfNDs. i-k: Fluorescence microscopy observation of an
AluDia agglomerate. Red fluorescence of AluDia particles excited by a 532 nm laser source (i). Alum of AluDia complex stained with Morin
and detected by a green fluorescence with a characteristic 520 nm emission when excited at 420nm (j), colocalization of the red fluorescence
of mfNDs and the green Morin fluorescence of alum (k), without alteration of the typical mfND emission spectrum (l). AluDia Alhydrogel® and
mfND complex, HPG hyperbranched polyglycerol, mfNDs modified fluorescent nanodiamonds, TEM transmission electron microscope
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plex was determined on the basis of different experimen-
tal assays. The respective proportions of the suspensions
Alhydrogel® and mfNDs were varied from 1/0.25 to 1/
100 and the resulting complex observed with fluorescent
microscopy and characterized by TEM. The final value
of 1/17 was chosen as the optimal compromise between
these two distant values. With the 1/0.25 ratio, mfNDs
were difficult to detect in the large amount of Alhydro-
gel® during TEM observations. At the inverse, with the
1/100 ratio, Alhydrogel® became almost the minor com-
ponent. The preparations of the AluDia complex were
based on the simple mixing of both solutions and their
agitation to favor the complex formation. The formed
particles had a micrometric size and they fell down rap-
idly to the bottom of the eppendorf. However, free
mfNDs gave stable suspensions and should then remainin the supernatant. The analysis of the latter in the mix-
ture case used in this study showed no free mfNDs.
HR-TEM imaging showed that mfNDs have a rounded
to polygonal shape (Fig. 1a). In addition to the mfND
size indicated by dynamic light scattering analysis, very
small mfNDs (a few nm) were detected within the mfND
aggregates by TEM. When excited by a laser at 532 nm,
mfNDs displayed a red fluorescence (Fig. 1b) with a spe-
cific luminescence spectrum peaking at 700 nm (Fig. 1c).
We attribute the favorable interactions created between
alum and mfNDs to the presence of numerous hydroxyl
groups on the polyglycerol chains synthesized at the sur-
face of mfNDs. Polyols were reported to be adsorbed
strongly at the surface of boehmite (AlOOH) particles and
hydrogen bonds were created between their hydroxyl
groups and AlOOH [21]. Thanks to the hyperbranched
structure of polyglycerol, numerous hydroxyl groups are
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thus create such hydrogen interactions with alum (Fig. 1d).
Although electrostatic interactions due to opposite zeta
potential values between mfNDs and Alhydrogel® cannot
be completely excluded, the contribution of this second
type of interaction to the stability of the complex should
almost disappear in the salty solutions (PBS 1x) that we
use due to the charge screening effect.
Both alum and vaccine particles displayed a nano-
fibrous morphology (Fig. 1e, f ), as previously reported in
the literature [22]. AluDia were distinctly composed of
nano-fibrous agglomerates of alum randomly decorated
by polygonal, non-fibrous, electron dense mfNDs
(Fig. 1g, h). This was confirmed by X-ray microanalysis
and high resolution transmission electron microscopy
(data not shown, see below). In bright field TEM images,
the mfNDs have various crystal orientations with respect
to the incident electron beam. The darker particles cor-
respond to nanocrystals in Bragg’s position on which the
electron beam has been diffracted and then stopped by
the objective aperture (Fig. 1a, g and h). AluDia particles
stained by Morin to detect aluminum showed colocaliza-
tion of the red fluorescence of mfNDs with the green
fluorescence of the Morin-alum complex, without alter-
ation of the typical mfND emission spectrum (Fig. 1i-l).
Thus, the association of mfNDs with alum does not dis-
turb the fluorescent signature of mfNDs. Taken together,
these results and the persistent colocalization observed
at distant places from the injection point in mice (as will
be shown later) strongly suggest that stable attractive in-
teractions are created between aluminum oxyhydroxide
and mfNDs. Moreover, fluorescence images (Fig. 1i-k)
show clearly that mfNDs are much more fluorescent
than alum stained by Morin which makes these particles
useful to detect isolated alum particles.
Morin stain was previously used in the paper from our
lab showing systemic translocation of Al particles [3].
However, Morin stain was reported to be not entirely
specific for Al. Browne et al. showed that Morin could
stain other metals but Al has the most of affinity to
Morin according to the following order: Al > Fe(III) >
Cu > Fe(II) > Ca > Mg > Mn = Zn [23]. Lumogallion
was reported as an interesting dye for aluminum studies
[24, 25]; however, it has limitations, too. Lumogallion
specificity for Al is higher than that of Morin but Lumo-
gallion also stains gallium, in addition to Al [26] and
other metals, such as Fe [27, 28]. Furthermore, both the
Lumogallion affinity for Al and fluorescence signal in-
tensity are much lower than those of Morin [29] limiting
its use when the detection of trace amounts of Al in tis-
sues is concerned, e.g. in brain. Additionally, the Lumo-
gallion red/orange fluorescence emission spectrum is
very close to that of the mfNDs we used, precluding its
use in place of Morin in the present study.In vivo observations
Granuloma formation at the injection site
At 21 days after i.m. injection, AluDia particles accumu-
lated into the injected muscle similarly to vaccine particles
[3]. Indeed, granuloma mainly composed of CD11b+
monocyte- macrophage lineage cells filled with AluDia
was formed in the endomysium, i.e. in between myofibers,
at the injection site (Fig. 2a). Non Morin-stained AluDia
particles in muscles have the same fluorescent signature
as compared to those of mfNDs (Fig. 2b,c). These particles
do not display any fluorescence when they are excited at
420nm as compared to Morin-stained AluDia (Fig. 2c).
The phase contrast image shows AluDia particles within
the granuloma region in muscle section (Fig. 2d). Morin
stain for aluminum confirmed that macrophages con-
tained stably associated AluDia particles as assessed by
both red and green fluorescence (Fig. 2e-g). Importantly,
photostability of mfNDs upon long laser exposure made
AluDia detection very easy without background fluores-
cence whereas the detection of Morin stain was com-
monly disturbed by its bleaching and a strong tissue
fluorescent background (Fig. 2h-j). Serial sectioning of the
injected muscle at day 45, day 135, day 180 and day 270
after AluDia injection showed progressive shrinkage of
muscle granulomas (Table 2), as previously reported in
rats [30]. At 270 days post-injection, one out of three
tested mice was completely free of muscle granuloma, and
the other two mice only had small residual muscle
granulomas.
AluDia translocation from the injected muscle to distant
organs
AluDia injected in the mouse tibialis anterior muscle was
followed by lymphatic and systemic particle biodistribu-
tion (Table 3), as previously reported with other fluores-
cent particles [3]. Alum and mfNDs remained clearly
colocalized in a large majority of particles detected re-
mote from the injection site as assessed by Morin stain
(Fig. 3a-i). Actually, our data of particle counting in
sections from various tissues showed that 88 ± 4 % of
observed nanodiamonds were close to those of alum.
Similarly to alum-rhodamine nanohybrid particles
(AlRho) used by Khan et al. [3], AluDia reached the in-
guinal dLN, as observed at day 7, and then left the dLN
which partially emptied at day 21. One striking obser-
vation was the marked increase of AluDia particles in
spleen at day 7 (54,500 particles) with a decrease at day
21 (7,000 particles). This massive alum access to spleen
at day 7 was not previously noted in the Khan et al.
study [3] which had no intermediate time points between
day 4 and day 21. This observation is in keeping with the
time frame of a primary immune response in the lymph-
oid organs. Particles were also detected in the liver, an
organ not studied by Khan et al. [3], but previously shown
Fig. 2 AluDia translocation and biopersistence in injected muscle after 21 days. a: immunohistochemistry analysis: AluDia particle accumulation in
the injected muscle inducing a granuloma of CD11b+ monocyte-macrophage lineage cells filled with AluDia in the endomysium area. The green
fluorescence corresponds to CD11b protein immunolabeling. b-d: AluDia particle detection (b) in injected muscle non-stained with Morin. Tissue
section was observed using the 420 nm excitation for Morin (c) and phase contrast (d). e-g: the stable association between the mfND component
as assessed by the red fluorescence obtained with the 532 nm laser excitation (e) and alum after Morin staining observed with 420 nm excitation
(f) and phase contrast image (g). h: mfND component of AluDia complex (red fluorescence) with alum component stained with Morin and
disturbed by the high fluorescent background of muscle cells (i) at the injection site in muscle section observed with phase contrast microscopy
analysis (j). AluDia Alhydrogel® and mfND complex, mfNDs modified fluorescent nanodiamonds
Table 2 Semi-quantitative study of the progressive decrease of granuloma size in injected muscle with AluDia complex. AluDia
Alhydrogel® and mfND complex, TA tibialis anterior
Days No granuloma (0) Small granuloma (+) Medium granuloma (++) Large granuloma (+++) Total
D45 2 % 13 % 24 % 61 % 100 %
D135 2 % 14 % 31 % 54 % 100 %
D180 36 % 22 % 9 % 19 % 100 %
D270 71 % 19 % 10 % 0 % 100 %
Whole TA muscle from three injected animals per time point (n = 3 per time point) were serially cryo-sectionned (a mean number of 90 longitudinal muscle
sections were obtained per animal). Each section was categorized into four groups: no granuloma (0), small (+), medium (++) and large (+++) granuloma. Then,
percentage of muscle section typing was calculated at each time point
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Table 3 AluDia particle systemic distribution at 7 and 21 days
after injection of an equivalent of 400 μg/Kg aluminum in the
tibialis anterior muscle. AluDia Alhydrogel® and mfND complex,
dLNs draining lymph nodes, mfNDs modified fluorescent
nanodiamonds
Organs mfND signals/organ at day 7 mfND signals/organ at day 21
dLNs 2552 ± 22 308± 16
Spleen 54507± 197 7000± 99
Liver 495 ± 84 2750± 56
Brain Not done 15± 4
Four mice were used in each experimental point (n = 4 per organ and per
time point). Results are mean ± SD
Fig. 3 Assessment of AluDia biodistribution following its injection in tibialis a
nodes which appeared mostly empty at day 21 (cf. Table 2). d-l: AluDia partic
Morin stain of aluminum revealed that mfNDs and alum were co-localized in
fluorescent nanodiamonds
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Besides additional insights provided by the evaluation of
different time points and additional organs, the use of
AluDia allowed us to substantiate our previous contention
that alum particles translocate from the injected muscle to
dLNs and then to distant organs unplugged to lymphatic
vessels [3].
Four brains were examined at day 21 after i.m. injec-
tion of AluDia. Consistent with the low level of cerebral
incorporation of particle previously noted at this early
time point [3], each of the four brains contained 15 ± 4
AluDia particles, usually forming small clusters in the
cerebellum or cerebral cortex. As shown in Fig. 3j-l,
Morin stain for aluminum revealed that mfNDs and
alum were colocalized in most particles, whereas occa-
sional particles were solely positive for either Morin+ ornterior muscle at day 21. a-c: AluDia translocation in inguinal lymphatic
les reach liver, spleen and brain forming small clusters. In all observations,
most particles. AluDia Alhydrogel® and mfND complex, mfNDs modified
ab
c
Fig. 4 Cell viability assayed by mitochondrial metabolism assessment
(MTT test). NSC-34 neuron-like cells were incubated with different
concentrations of mfNDs, alum and AluDia particles for 72 hours.
AluDia concentrations tested in (c) = mfNDs concentrations in (a) +
alum concentrations in (b). a: mfNDs particles are non-toxic, except
at the highest dose. b: alum particles display a toxic or severely toxic
effect at all doses used. c: AluDia particles have no supplemental toxicity
compared to alum alone. Viability was normalized to the value
determined in untreated cells. Results are expressed as mean ±
standard deviation. Cells were obtained from four different cultures
to realize four biological replications (n = 4). Viability measurement
of each concentration point was repeated 12 times. *Significant
difference at p < 0.05. AluDia Alhydrogel® and mfND complex,
mfNDs modified fluorescent nanodiamonds
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confers physicochemical properties to the neo-particle
that are very similar to whole vaccine particles, these
data definitely establish that bona fide alum adjuvants of
vaccines can penetrate in the brain [3]. This occurs in
the particulate form and mimics brain translocation of
infectious particles, such as intracellular bacteria, HIV
and other pathogens [32–34].
Finally, AluDia particles confirmed the biodistribution
modalities of poorly degradable particles. In addition, Alu-
Dia particles were well characterized whereas previously
used AlRho particles had undetermined size, zeta poten-
tial, ultrastructure and proportion relative to alum. In
addition to good relevance to vaccine, AluDia particles
allowed administration of precise amounts of aluminum.
In vitro observations
Cytotoxicity
Since little has been reported about toxic effects of alum
in vitro, we examined next whether AluDia particles
could be used in vitro to study what could be the impact
of alum on cultured cells. In order to compare the cyto-
toxicity of alum and AluDia particles, we incubated
NSC-34 neuronal lineage cells with different concentra-
tions of mfNDs, Alhydrogel®, and AluDia particles for 72
hours. Particle toxicity was evaluated based on cell via-
bility assessed by MTT assay relative to controls, as pro-
posed by Kong et al. [35]: (1) non-toxic >90 % cell
viability; (2) slightly toxic = 65–90 %; (3) toxic = 35–65 %;
(4) severely toxic ≤35 %. mfNDs appeared non-toxic, ex-
cept at the highest dose (Fig. 4a), confirming previous re-
ports on the lack of toxicity of nanodiamonds [36, 37].
Paget et al. showed that mfNDs are neither cytotoxic nor
genotoxic on six human cell lines representative of poten-
tial target organs: HepG2 and Hep3B (liver), Caki-1 and
Hek-293 (kidney), HT29 (intestine) and A549 (lung) [38].
These authors did not check mfNDs cytotoxicity on
neural cell lines, but Hsu et al. reported that mfNDs dis-
turb neither neuronal differentiation nor neuron functions
[14]. In addition, mfNDs were shown to be non-toxic
in vivo, in both Caenorhabditis elegans and mouse [39,
40]. However, other studies showed slight toxic and ge-
notoxic effects of nanodiamonds in vitro and in vivo
[41–43]. Only a few studies reported serious toxic effects
in vivo [44, 45].
In contrast to mfNDs, alum particles were toxic or se-
verely toxic at all doses used (Fig. 4b), and the same was
observed with AluDia (Fig. 4c). AluDia had no supple-
mental toxicity compared to Alhydrogel® particles
alone. Interestingly, with both Alhydrogel® and AluDia,
cytotoxity did not show a linear dose–response, since
higher doses tended to be less toxic than intermediate
doses, as previously noted for particle toxicity [46–49].
Alhydrogel® in vitro toxicity for neuronal cells is inkeeping with mouse studies showing in vivo neurotoxic
effects of subcutaneously administered Alhydrogel®, in-
cluding neural apoptosis and both motor and behav-
ioral deficits [50].
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Electron microscopy was performed on THP-1 mono-
cyte/macrophage lineage cells incubated with AluDia
particles. Particles were internalized by THP-1 cells
within hours (Fig. 5a and b). After 24 hours AluDia par-
ticles were often found in large intracellular structures
that may suggest macropinosomes, as was reported by
Alhaddad et al. for siRNA delivery by nanodiamonds
[51]. However, macropinosomes filled with AluDia parti-
cles often have damaged membranes (Fig. 5c and f). This
observation was in line with the toxicity of alum for
membrane lipid bilayers [52–54]. It seems possible that
alum crystals directly aggress membranes [55], and this
may play a crucial role in its adjuvant effect by inducing
lysosomal function blockade [52–55]. Another mechan-
ism of endosomal membrane damage may be related to
nanomaterial-induced oxidative stress [56], and, indeed,
aluminum [57], but not nanodiamonds [58], induces sig-
nificant oxidative stress.Fig. 5 Ultra-structure observations by TEM of AluDia interaction with THP-1 m
for 3 (a) or 24h (b-i). a and b: AluDia particle internalization by THP-1 cell
macropinosome. Black (b,c) and white (c) arrows indicate macropinosom
particles encircled by double membrane autophagosome (arrow) indicati
emission peak of (h) region, of internalized AluDia, by the X-ray microana
resolution TEM analysis of the endosome content identified the specific c
pseudo-colors, are superimposed to show the two crystalline structures o
and mfND complex, mfNDs modified fluorescent nanodiamonds, TEM tranAnother ultrastructural finding after 24-hour AluDia ex-
posure consisted in intracellular particles encircled by
double membranes highly suggestive of autophagophores,
thus assessing active autophagy (Fig. 5d). Cells coping with
microbes use a dedicated form of autophagy termed
“xenophagy” as a host defense mechanism to engulf and
degrade intracellular pathogens. The same holds true for
inert particles subjected to phagocytosis/endocytosis [59].
Eidi et al. reported that the free internalized particles in
cell cytoplasm could induce stress of mitochondria or
other intracellular organelles resulting in autophagy acti-
vation [56]. As mentioned above, alum particles are toxic
to membranes which destabilizes phagosomes and lyso-
somes, triggers inflammasome assembly, and impedes the
autophagy pathways [52–55]. It seems possible that mac-
rophages that perceive the foreign particles in their cyto-
sol, just like senescent organelles or bacteria, will attempt
to reiterate the autophagic process until they dispose of
the alien materials. The compartmentalization of particlesonocyte cell line. Cells were treated with 20 μg/mL of AluDia particles
s. Arrows indicate endosome membranes. c: AluDia particles inside
e membrane and its absence, respectively. d: Intracellular AluDia
ng the autophagy activation. e: Detection of aluminum specific
lysis (EDX). f: macropinosome filled with AluDia particles. g- i: High
rystal periodicity of mfNDs, (h): red (mfNDs) and green (alum)
f the AluDia complex (yellow pseudo-color, i). AluDia Alhydrogel®
smission electron microscopy
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hagosomes with repaired and re-acidified lysosomes could
expose alum particles to lysosomal acidic pH, a crucial
factor in the alum solubilization process. Notably, Li et al.
reported that alpha-alumina nanoparticles activate the au-
tophagy in dendritic cells much more efficiently than alum
particles [60]. To our knowledge, no study in the literature
has reported autophagy activation by mfNDs.
It is difficult to visualize moderate amounts of alum
within cells by TEM, and one has to use X-ray micro-
analysis (EDX) to assess the presence of aluminum by
detection of a specific emission peak (Fig. 5e). This ap-
proach has limitations since the sample is always at risk
of being contaminated by extrinsic aluminum present in
the air or incorporated into the sample during its pro-
cessing. The use of AluDia may help in tracking alum in
resin embedded material. MfNDs cannot represent con-
taminants and their specific and highly photostable fluor-
escence can be detected in semi-thin sections. Moreover,
high resolution TEM can reliably identify the specific crys-
talline structures. As shown in Fig. 5f-i, high resolution
TEM of the endosome content of THP1 cells exposed
to AluDia identified the specific crystal periodicity of
both mfNDs (red pseudo-color) and Alhydrogel® (green
pseudo-color), as well as superimposition of the two
crystalline structures (yellow pseudo-color). This confirmed
the stability of AluDia after internalization by immune cells.
Using mfNDs as a tag mimicing vaccine antigen, the same
approach could be used to assess if and how the alum adju-
vant dissociates from compounds adsorbed at its surface
over a long time in vivo.
Conclusion
We developed a tracking method for aluminum adjuvant
particles to be able to understand their fate, residence
time, putative accumulation and impact on organs and the
organism based on their labeling with functionalized
nanodiamonds. The detection of mfNDs by photolumi-
nescence is easy to implement at different scales and al-
lows a detailed estimation of biodistribution in organs and
the organism down to the subcellular level. Adjuvant par-
ticle labeling with mfNDs affects neither their physico-
chemical characteristics nor their biological effects. Thus,
fluorescent nanodiamonds modified by hyperbranched
polyglycerol appear to be a biocompatible and original
tool to address all aspects of alum biodisposition.
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